Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET

Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (V...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 19; no. 8; pp. 2971 - 2979
Main Authors Lambidis, Elisavet, Chen, Chun-Chieh, Baikoghli, Mo, Imlimthan, Surachet, Khng, You Cheng, Sarparanta, Mirkka, Cheng, R. Holland, Airaksinen, Anu J.
Format Journal Article
LanguageEnglish
Published American Chemical Society 01.08.2022
Subjects
DOTA
hepatotropism
gallium-68
hepatitis E viral nanoparticles
virus-like particle
positron emission tomography tracers
Online AccessGet full text

Cover

Abstract Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]­Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]­Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.
AbstractList Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [ 68 Ga]Ga-DOTA-HEVNPs was studied in mice. The results indicated that [ 68 Ga]Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the ability to reach sites beyond biological barriers, and the delivery of higher cargo concentrations to diseased sites. Virus-like particles (VLPs) can efficiently be used for targeted delivery purposes. VLPs are derived from the coat proteins of viral capsids. They are self-assembled, biodegradable, and homogeneously distributed. In this study, hepatitis E virus (HEV) VLP derivatives, hepatitis E virus nanoparticles (HEVNPs), were radiolabeled with gallium-68, and consequently, the biodistribution of the labeled [68Ga]­Ga-DOTA-HEVNPs was studied in mice. The results indicated that [68Ga]­Ga-DOTA-HEVNPs can be considered as promising theranostic nanocarriers, especially for hepatocyte-targeting therapies.
Author Sarparanta, Mirkka
Imlimthan, Surachet
Airaksinen, Anu J.
Baikoghli, Mo
Khng, You Cheng
Cheng, R. Holland
Lambidis, Elisavet
Chen, Chun-Chieh
AuthorAffiliation Department of Molecular and Cellular Biology
University of Turku
University of California
Department of Chemistry, Radiochemistry
University of Helsinki
Turku PET Centre, Department of Chemistry
AuthorAffiliation_xml – name: Department of Chemistry, Radiochemistry
– name: University of California
– name: Department of Molecular and Cellular Biology
– name: University of Turku
– name: University of Helsinki
– name: Turku PET Centre, Department of Chemistry
Author_xml – sequence: 1
  givenname: Elisavet
  surname: Lambidis
  fullname: Lambidis, Elisavet
  organization: University of Helsinki
– sequence: 2
  givenname: Chun-Chieh
  surname: Chen
  fullname: Chen, Chun-Chieh
  organization: University of California
– sequence: 3
  givenname: Mo
  surname: Baikoghli
  fullname: Baikoghli, Mo
  organization: University of California
– sequence: 4
  givenname: Surachet
  orcidid: 0000-0003-2520-2146
  surname: Imlimthan
  fullname: Imlimthan, Surachet
  organization: University of Helsinki
– sequence: 5
  givenname: You Cheng
  surname: Khng
  fullname: Khng, You Cheng
  organization: University of Helsinki
– sequence: 6
  givenname: Mirkka
  orcidid: 0000-0002-2956-4366
  surname: Sarparanta
  fullname: Sarparanta, Mirkka
  organization: University of Helsinki
– sequence: 7
  givenname: R. Holland
  surname: Cheng
  fullname: Cheng, R. Holland
  email: rhch@ucdavis.edu
  organization: University of California
– sequence: 8
  givenname: Anu J.
  orcidid: 0000-0002-5943-3105
  surname: Airaksinen
  fullname: Airaksinen, Anu J.
  email: anu.airaksinen@utu.fi
  organization: University of Turku
BookMark eNpVkU1v1DAQhi1URD_gP5gblyz-ShxfkFB3aZFWwGHhak28k11XSRxsZ6v-e1x1hdTLzGjm1at59VyTiylMSMhHzlacCf4ZXFqNYZiPEEdwuOSVcIzJ2rwhV7xWsmqlERf_51ZdkuuUHhgTqhbyHbmUdVtrJcwVCWs84RDmEadMQ0-b9g6qLXQ44J7e4wzZZ5_ohv7xcUn0B0xhhpi9GzDRPkS6g3jAXMTruBzoGgd_wvhEYSobD4cppCJO9NHnI_212b0nb3sYEn449xvy-9tmd3tfbX_efb_9uq1AaJYrJ7XqRCMaWQuDXPTQlIDacW7a3nStUEoL1PvWiH2pDrpWQW8aprV2Umh5Q768-M5LN-LelXgRBjtHP0J8sgG8fX2Z_NEewskaqZqGi2Lw6WwQw98FU7ajTw6HASYMS7KiMYLp8qAs0vpFWrjYh7DEqSSznNlnWPZ5-QqWPcOS_wABrY6h
ContentType Journal Article
Copyright 2022 The Authors. Published by American Chemical Society
2022 The Authors. Published by American Chemical Society 2022 The Authors
Copyright_xml – notice: 2022 The Authors. Published by American Chemical Society
– notice: 2022 The Authors. Published by American Chemical Society 2022 The Authors
DBID 7X8
5PM
DOI 10.1021/acs.molpharmaceut.2c00359
DatabaseName MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1543-8392
EndPage 2979
ExternalDocumentID PMC9346612
a610518504
GrantInformation_xml – fundername: ;
  grantid: CA198880
– fundername: ;
  grantid: 318422
– fundername: ;
  grantid: EB021230
– fundername: ;
  grantid: 298481
– fundername: ;
  grantid: 320102
– fundername: ;
  grantid: NA
– fundername: ;
  grantid: CA225266
– fundername: ;
  grantid: CADMCB-7399-H
– fundername: ;
  grantid: TR002866
GroupedDBID -
123
4.4
53G
55A
5VS
7~N
AABXI
ABFRP
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
CS3
DU5
EBS
ED
F5P
GGK
GNL
H~9
IH9
JG
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
7X8
ABBLG
ABJNI
ABLBI
ABQRX
ADHLV
BAANH
CUPRZ
ED~
JG~
5PM
ID FETCH-LOGICAL-a270t-c374b26263529e12fa60037c1198f9b824472e7d892d7d8cab84af960777c3273
IEDL.DBID ACS
ISSN 1543-8384
1543-8392
IngestDate Thu Aug 21 14:12:48 EDT 2025
Fri Jul 11 02:10:30 EDT 2025
Wed Aug 03 13:56:57 EDT 2022
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords DOTA
hepatotropism
gallium-68
hepatitis E viral nanoparticles
virus-like particle
positron emission tomography tracers
Language English
License Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a270t-c374b26263529e12fa60037c1198f9b824472e7d892d7d8cab84af960777c3273
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-5943-3105
0000-0002-2956-4366
0000-0003-2520-2146
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9346612
PMID 35857429
PQID 2692072633
PQPubID 23479
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9346612
proquest_miscellaneous_2692072633
acs_journals_10_1021_acs_molpharmaceut_2c00359
PublicationCentury 2000
PublicationDate 20220801
PublicationDateYYYYMMDD 2022-08-01
PublicationDate_xml – month: 08
  year: 2022
  text: 20220801
  day: 01
PublicationDecade 2020
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2022
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
SSID ssj0024523
Score 2.3924344
Snippet Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the...
Targeted delivery of diagnostics and therapeutics offers essential advantages over nontargeted systemic delivery. These include the reduction of toxicity, the...
SourceID pubmedcentral
proquest
acs
SourceType Open Access Repository
Aggregation Database
Publisher
StartPage 2971
Title Development of 68Ga-Labeled Hepatitis E Virus Nanoparticles for Targeted Drug Delivery and Diagnostics with PET
URI http://dx.doi.org/10.1021/acs.molpharmaceut.2c00359
https://www.proquest.com/docview/2692072633
https://pubmed.ncbi.nlm.nih.gov/PMC9346612
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkRAX3ojlJVdCPdXLxnZi54jaLSuE0EqkqLfIr5QVkKBNclh-PWMn1TZwQL3k4FiJY4_jbzzffAZ4iy6HyoXV1Jk0o8K7nCqfcZpK5mXFfWVcZFt8zlbn4uNFerHP4_47gs-Sd9q2859NSDwdt3jnzEbhudtwh2U4mQMeOvmyF9hL45luCA04VVyJu3D430eFpcm2E5A5pUheW3POHkBxlbkzUE2-z_vOzO3vf4Ucb_I5D-H-iEHJ-8FoHsEtXz-Go_VQd3dMin1OVntMjsh6L2-9ewLNNZ4RaSqSqQ-aftIG1y9HVj4wtLtNS5bk62bbtwR_3-iXj_Q7ghCZFJF8jpVPt_0lOfU_AjVkR3SNJQPxL7yYhB1isl4WT-H8bFmcrOh4bAPVTC46arkUhkWVG5b7hFU6Cyo3NklyVeVGIaAIhuBUzhxerTZK6Ao9KSml5QinnsFB3dT-OZAF98JxXSnGnVCIbbxLeZUZ7kM0WKczQKtry3HatWWMqLOkDIWTTi7HTp7B4dUQlziPQnBE177p25JlOVtIbDSfgZyMfflr0P0ogxL39E69-RYVuXMuEOewFzdtzku4x0I6RSQUvoKDbtv71whyOvMmGvUfY7v9wA
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB1BkaAXvhHLpyuhnurtxk5i51i1WxZYqpVIUSUOlh07sCokaJMcll_P2BvYhguCSw6O5UyccfzsefMM8AqXHDKLC02tSVIaO5tR6VJOE8GcKLkrjQ1si7N0dh6_vUguelalz4VBIxpsqQlB_K26QHToy77VPv-03-kdsyLoz12HGwhKmPfuo-MPW529JBzthgiBU8llfBP2_tqUn6GKZoA1h0zJK1PP6R349NvowDi5HHetGRc__tBz_L-3ugu3e0RKjjYudA-uueo-7C82ddcHJN9maDUHZJ8stmLX6wdQX2EdkbokqXyt6VwbnM0smTnP126XDZmSj8tV1xD8meMqvSfjEQTMJA9UdKx8suo-kxP31RNF1kRXWLKhAfoHE79fTBbT_CGcn07z4xntD3GgmolJSwsuYsOC5g3LXMRKnXrNmyKKMllmRiK88G5hZcYsXgttZKxLXFcJIQqO4OoR7FR15R4DmXAXW65LybiNJSIdZxNepoY7HxvWyQh8H6t-EDYqxNdZpHzhoJNV38kj2Pv1pRWOKh8q0ZWru0axNGMTgUbzEYiBC6jvGxUQ5XW5h3eq5Zegz53xGFEPe_Kv5ryEW7P8_VzN35y9ewq7zCdaBKrhM9hpV517jvCnNS-Cn_8EwPYGMA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZgSBOX8VuUn56EdlpKYzuxc5zWlgLTVIkO7WbZscOqjWRqkkP31-89N9CFC4JLDo7lvDjP8We_730m5AMsOVQmchM5m6SR8C6LlE95lEjmZcF9YV1gW5ymszPx5Tw57zbcMBcGjKihpToE8XFUX7uiUxiIP2L5zwpzULvd3iHLgwbdffIAw3fo4UfH37Zae0k43g1QAo8UV2KX7P-1KZyl8rqHN_tsyTvTz_QR0b8ND6yTy2Hb2GF-84em4_-_2WOy1yFTerRxpSfkni-fkoP5pu76kC62mVr1IT2g863o9foZqe6wj2hV0FR9MtGJsTCrOTrzyNtuljWd0O_LVVtT-KnDar0j5VEAznQRKOlQebxqf9Cxv0LCyJqaEko2dEB8MMV9YzqfLJ6Ts-lkcTyLusMcIsPkqIlyLoVlQfuGZT5mhUlR-yaP40wVmVUAM9A9nMqYg2turBKmgPWVlDLnALJekJ2yKv1LQkfcC8dNoRh3QgHi8S7hRWq5xxixSQYE-1l3g7HWIc7OYo2FvU7WXScPyP6vr61hdGHIxJS-amvN0oyNJBjNB0T23EBfb9RANOpz9--Uy4ug051xAeiHvfpXc96T3fl4qk8-n359TR4yzLcIjMM3ZKdZtf4toKDGvguufgsN7giz
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+68Ga-Labeled+Hepatitis+E+Virus+Nanoparticles+for+Targeted+Drug+Delivery+and+Diagnostics+with+PET&rft.jtitle=Molecular+pharmaceutics&rft.au=Lambidis%2C+Elisavet&rft.au=Chen%2C+Chun-Chieh&rft.au=Baikoghli%2C+Mo&rft.au=Imlimthan%2C+Surachet&rft.date=2022-08-01&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=19&rft.issue=8&rft.spage=2971&rft.epage=2979&rft_id=info:doi/10.1021%2Facs.molpharmaceut.2c00359&rft.externalDocID=a610518504
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon